Discovery of TRV130, a G protein biased agonist of the μ-opioid receptor, for the treatment of acute severe pain

被引：0
|
作者：
Crombie, Aimee [1 ]
Chen, Xiao-Tao [1 ]
Pitis, Philip [1 ]
Liu, Guodong [1 ]
Yuan, Catherine [1 ]
Gotchev, Dimitar [4 ]
Yamashita, Dennis [3 ]
Violin, Jonathan [2 ]
机构：
[1] Trevena Inc, Chem, King Of Prussia, PA USA
[2] Trevena Inc, Biol, King Of Prussia, PA USA
[3] GSK, Discovery Partnerships Acad, Boston, PA USA
[4] Teva Pharmaceut, Chem, W Chester, PA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2015年 / 249卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
34
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain
    Viscusi, Eugene R.
    Webster, Lynn
    Kuss, Michael
    Daniels, Stephen
    Bolognese, James A.
    Zuckerman, Seth
    Soergel, David G.
    Subach, Ruth Ann
    Cook, Emily
    Skobieranda, Franck
    PAIN, 2016, 157 (01) : 264 - 272
  • [2] THE EFFECT OF A G-PROTEIN BIASED LIGAND, TRV130, ON OPIOID-INDUCED CONSTIPATION
    Jacob, Joanna C.
    David, Bethany
    Khan, Aliyeen
    Dewey, William L.
    Akbarali, Hamid I.
    GASTROENTEROLOGY, 2018, 154 (06) : S758 - S758
  • [3] Abuse-related effects of the biased mu opioid receptor agonist trv130 on intracranial selfstimulation in rats
    Altarifi, Ahmad
    Blough, Bruce
    Negus, S. Steven
    DRUG AND ALCOHOL DEPENDENCE, 2017, 171 : E7 - E7
  • [4] The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats
    Zamarripa, C. Austin
    Edwards, Shelley R.
    Qureshi, Hina N.
    Yi, John N.
    Blough, Bruce E.
    Freeman, Kevin B.
    DRUG AND ALCOHOL DEPENDENCE, 2018, 192 : 158 - 162
  • [5] Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents
    Altarifi, Ahmad A.
    David, Bethany
    Muchhala, Karan H.
    Blough, Bruce E.
    Akbarali, Hamid
    Negus, S. Stevens
    JOURNAL OF PSYCHOPHARMACOLOGY, 2017, 31 (06) : 730 - 739
  • [6] First Human Dosing Experience with TRV130, a Biased Ligand at the Mu Opioid Receptor
    Soergel, David
    Subach, Ruth Ann
    Violin, Jonathan
    Yamashita, Dennis
    Gowen, Maxine
    Lark, Michael
    NEUROLOGY, 2013, 80
  • [7] ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The μ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy
    Bergese, Sergio D.
    Brzezinski, Marek
    Hammer, Gregory B.
    Beard, Timothy L.
    Pan, Peter H.
    Mace, Sharon E.
    Berkowitz, Richard D.
    Cochrane, Kristina
    Wase, Linda
    Minkowitz, Harold S.
    Habib, Ashraf S.
    JOURNAL OF PAIN RESEARCH, 2019, 12 : 3113 - 3126
  • [8] Modeling Opioid Maintenance Therapy in Rats: Effects of Chronic Buprenorphine and the Biased Mu-Opioid Receptor Agonist TRV130 on Relapse to Oxycodone Seeking
    Shaham, Yavin
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S65 - S66
  • [9] The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels
    Yudin, Yevgen
    Rohacs, Tibor
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (17) : 3110 - 3125
  • [10] In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia
    Bossert, Jennifer M.
    Kiyatkin, Eugene A.
    Korah, Hannah
    Hoots, Jennifer K.
    Afzal, Anum
    Perekopskiy, David
    Thomas, Shruthi
    Fredriksson, Ida
    Blough, Bruce E.
    Negus, S. Stevens
    Epstein, David H.
    Shaham, Yavin
    BIOLOGICAL PSYCHIATRY, 2020, 88 (12) : 935 - 944
12345